Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) FCF Margin (2023 - 2025)

Historic FCF Margin for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to 1252.95%.

  • Immunome's FCF Margin fell 1640800.0% to 1252.95% in Q2 2025 from the same period last year, while for Sep 2025 it was 1982.0%, marking a year-over-year decrease of 10679000.0%. This contributed to the annual value of 1304.8% for FY2024, which is 12448800.0% down from last year.
  • Immunome's FCF Margin amounted to 1252.95% in Q2 2025, which was down 1640800.0% from 1938.48% recorded in Q1 2025.
  • Over the past 5 years, Immunome's FCF Margin peaked at 1013.11% during Q1 2023, and registered a low of 1938.48% during Q1 2025.
  • In the last 3 years, Immunome's FCF Margin had a median value of 1157.94% in 2024 and averaged 821.36%.
  • Per our database at Business Quant, Immunome's FCF Margin tumbled by -23089300bps in 2024 and then plummeted by -1640800bps in 2025.
  • Immunome's FCF Margin (Quarter) stood at 465.45% in 2023, then tumbled by -239bps to 1577.28% in 2024, then increased by 21bps to 1252.95% in 2025.
  • Its FCF Margin was 1252.95% in Q2 2025, compared to 1938.48% in Q1 2025 and 1577.28% in Q4 2024.